Befesa S.A.

  • WKN: A2H5Z1
  • ISIN: LU1704650164
  • Land: Luxemburg

Nachricht vom 17.09.2021 | 11:56

DGAP-DD: Befesa S.A. deutsch

Befesa S.A.: Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
17.09.2021 / 11:55
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.



Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

17 September 2021

1. Details of the person discharging managerial responsibilities/person closely associated
Name Helmut Wieser
2. Reason for the notification
Position / status Member of the Board of Directors
Initial notification / amendment Initial notification
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
Name Befesa S.A.  
LEI 222100VXGA8L6J4ZWG61  
4. Details of the transaction(s)
section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
Description of the financial instrument, type of instrument Shares
Identification code7 LU1704650164
Nature of the transaction Gift of 220 shares (received)
Price(s) and volume(s) Price per share Volume
€0.00 220
Aggregated information  
- Aggregated volume    
- Price  
Date of the transaction 15 September 2021
Place of the transaction Outside a trading venue


Company information
Befesa S.A.
46, Boulevard Grande-Duchess Charlotte
L-1330 Luxembourg, Grand Duchy of Luxembourg
Contact: Rafael Pérez
Email: Internet:

17.09.2021 Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten, Corporate News/Finanznachrichten und Pressemitteilungen.
Medienarchiv unter

show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021